A study showed that hospitals bought by private equity firms were admitting disproportionately healthier patients with heart ...

Under terms of the deal, CSPC will receive $110 million upfront, with potential milestone payments reaching up to $5.22 ...

When the amount of cholesterol in the blood is too high, hypercholesterolemia can develop, causing serious damage to the ...

A new method, based on the use of molecules known as polypurine hairpins, facilitates the uptake of cholesterol by cells and ...

Enlicitide decanoate demonstrated meaningful LDL lowering in patients with heterozygous familial hypercholesterolemia and ...

When the amount of cholesterol in the blood is too high, hypercholesterolemia can develop, causing serious damage to the ...

Currently available PCSK9-targeting therapies are Amgen's Repatha (evolocumab) and Sanofi/Regeneron's Praluent (alirocumab), ...

AstraZeneca (AZ) and CSPC Pharmaceuticals Group have entered into a partnership worth up to $5.3bn to develop therapies for ...

Topline data were announced from two phase 3 trials evaluating enlicitide decanoate for the treatment of adults with hyperlipidemia.

Specifically, the team has designed a strategy to inhibit the expression of PCSK9, a protein that plays a decisive role in modulating plasma levels of low-density lipoprotein cholesterol (LDL-C).

Specifically, the team has designed a strategy to inhibit the expression of PCSK9, a protein that plays a decisive role in modulating plasma levels of low-density lipoprotein cholesterol (LDL-C).